The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult ...

MD, CFPC, FCFP, Family Physician, discusses What is Chronic Obstructive Pulmonary Disease.

Explore the future of the COPD market with our comprehensive report covering 68 geographic markets. Forecast drug sales growth from $17.4B in 2023 to $42.2B by 2033, driven by the US market. Gain ...

New tools, treatment options, and precision medicine developments are leading to better quality of life and survival for ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...

For reduced risk of chronic disease and a better chance at a longer life, midlife weight loss may be helpful, a new study ...

HealthDay News — Certain groups of physical multimorbidity may be associated with a higher risk of subsequent depression, according to a study published online May 13 in Communications Medicine.

as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD). Nucala stands out as the only approved biologic that has been ...

"At Sanofi, we’re excited to collaborate with Viz.ai to further address unmet needs in COPD care by leveraging AI," said Paul Rowe, MD, ATSF & Head of Medical, Specialty Care at Sanofi. “With this ...